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1.Cancer 
1.1 Introduction  
Cancer is a major burden of disease worldwide, as the leading cause of death in 
economically developed countries, and the second leading cause of death in developing 
countries.  
Its increase is mostly a result of population ageing and growth as well as an effect of the 
adoption of cancer-associated lifestyle choices including smoking, physical inactivity and 
‘‘westernized’’ diets. As elderly people are most susceptible to cancer and population 
ageing continues in many countries, it will remain a major health problem around the 
globe. 
Each year, tens millions of people are diagnosed with cancer around the world, and more 
than half of the patients eventually die from cancer.  
In many countries, it ranks the second most common cause of death following 
cardiovascular diseases, even if with the improvement in treatment and prevention of 
these last, cancer will soon become the number one killer in many parts of the world. [1]  
 
1.2 Pathogenesis 
Tumor is a disease characterized by an aberrant structure and uncontrolled growth of 
cells. The alterations that transform normal cells in neoplastic cells are usually structural 
(mutations) or, more rarely, functional. [2]  
Depending on morphological characteristics, methods of growth and behavior toward 
neighbouring tissues, tumors can be classified in benign and malignant tumors. 
The first ones enlarge but not invade surrounding tissues, have a cohesive structure and 
are delimited by a fibrous capsule; the latters are generally more dangerous because they 
invade tissues and spread to sites far from the place of origin (metastasis, which involves 
the formation of secondary tumors). Malignant tumors can indeed permeate blood and 
lymphatic vessels, and it is not uncommon the possibility of relapse, the recurrence of 
cancer in the same anatomical location after surgical removal. Furthermore, the 
invasiveness is one of the most important features to distinguish malignant from benign 
tumors. 
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The peculiarity that unites all of the cancer cells is the loss of control mechanisms of 
growth. 
Mutations responsible for the formation of the tumor involve 3 different classes of genes: 
 Oncogenes: genomic sequences (originated from proto-oncogenes) which are 
directly involved in the neoplastic transformation; their overexpression or 
functional modification alters the regulatory function of proteins involved in 
cellular growth. Mutations that convert proto-oncogenes in oncogenes are always 
activating mutations, and only one single copy of the mutated gene is sufficient 
for the oncogenic action, since oncogenes have dominant phenotype.  
 Tumor suppressor genes: or oncosuppressors, are recessive genes, which means 
that both of the allelic copies have to be mutated to cause the loss of their 
function. In particular, inactivated mutations are involved, such as gene deletions 
or gene silencing determining the functional inactivation of the gene itself.  
 Mutated genes: directly and functionally involved in the earlier phases of the 
neoplastic process. Their expression serves to maintain the genomic integrity and 
stability; molecular modifications of these genes increase the possibility of 
mutations in other genes implicated in oncogenesis.  
 
1.3 Factors affecting the development of cancer 
There are several factors that may influence the onset and development of cancer; in 
particular, studies on the epidemiology and incidence of cancer prove a correlation 
between the disease and different parameters, which can be divided into two categories: 
intrinsic factors and extrinsic factors. 
The first ones are transmitted from parents to the progeny and include: 
-Age: it has a significant influence on the probability of developing cancer: even if it can 
affect people of any age, the majority of cancers occur in older age. Cancer is the main 
cause of death among women aged between 40 and 79 years and among men between 
60 and 79 years. Cancer deaths decrease in over 80 reflects the lower number of subjects 
reaching this age, but this trend will go modifying the coming decades, since it will 
increase the number of elderly individuals in the population. 
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-Gender: because there are differences on the type of cancer developed between the 
male and female population. 
-Other parameters such as race, hormonal imbalances and genetic predisposition to 
mutations. 
The extrinsic factors instead, are all external such as: 
-Environment factors: there are significant differences in the incidence and mortality 
rates of various cancers in relation to geographical factors. This underlines the 
importance of cultural and environmental factors. 
-Physical agents considered to be carcinogenic are ultraviolet and ionizing radiations. 
Many epidemiological investigations have shown that ultraviolet radiations from sunlight 
or artificial sources play an important role in the etio-pathogenesis of some skin tumors. 
Oncogenic power of UV is related to their ability to induce mutations in target cells DNA. 
Biological results of this mutation are enzyme inactivation, cell division alterations, 
mutagenesis, cell death (necrosis) and cancer. Ionizing radiations are a risk factor for the 
insurgence of solid tumors, especially for lungs and for leukemia. There is a direct toxic 
action, following absorption of radiation by DNA, that can cause breaking of one or both 
filaments, distortion and breakage of bases and formation of cross-links, all ending with 
cell death or mutations. Indirect toxic action is instead triggered by the transfer of energy 
to the water within the cells, causing the formation of free radicals, and a consequent 
oxidative damage [2]. 
-Further external factors like smoking, air pollution, sedentary life, excessive consumption 
of alcohol, physical agents, chemicals and viruses. 
 
1.4 Anticancer therapy 
Therapy for cancer treatment differs depending on type and stage of the tumor, but it can 
be identified with common strategies that include surgery, radiotherapy and 
chemotherapy. 
The surgery is the most used therapy in case of solid tumor, it is indeed appropriate to 
remove the tumor and surrounding tissues that may contain cancer cells. Unfortunately, a 
problem occurred with this type of treatment relates to the spread of metastasis, caused 
by the displacement of neoplastic cells. 
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Also radiotherapy is useful as a primary therapy in some local tumors, and can be used in 
association whit surgery and chemotherapy, reducing in that case the possibility of 
relapse. It works by destroying cancer cells, but it may also damage normal cells, even if 
they can usually repair themselves.  
Chemotherapy is instead based on the systemic administration of more drugs, and it is 
used in combination with the other two types of therapies. The main problem that occurs 
with this therapy is about the side effects, because the drugs used are not perfectly 
selective towards tumor cells, but they explain their toxicity also on normal cells 
(especially on hematopoietic system). 
Chemotherapy can be further classified in monochemotherapy and polychemotherapy. 
The first is generally used with patients aged 70-75 years or older and it is the first choice 
for tumors as non-Hodgkin lymphoma or anaplastic thyroid cancer. The most used is 
actually the polychemotherapy. The synergism of more anticancer drugs enhances the 
therapeutic activity and reduces the toxicity of the single drug, changing the dosage and 
time of administration.  
 
1.5 Antitumor drugs 
Chemotherapy drugs can be divided into several groups based on factors such as how 
they work, their chemical structure, and their relationship with another drug. Some drugs 
act in more than one way, and may belong to more than one group. Knowing how the 
drug works is important in predicting its side effects.  
Usual targets of cytotoxic therapy are the main processes involved in cell proliferation, 
such as the functions of DNA and cell division. In fact, the drugs used to treat cancer act 
by the induction of cell cycle arrest or programmed cell death (apoptosis); in this regard, 
there are two categories of drugs: 
- Phase-specific: drugs are active on the neoplastic cells only in a specific phase of 
the cell cycle (for example, S phase for antimetabolites and M phase for Vinca 
alkaloids); 
- Phase-non-specific: drugs are active in any phase of the cell cycle (alkylating 
agents, antibiotics). 
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What differentiates these two categories of drugs is the number of cells that can 
kill; in fact, the phase-specific anticancer agents act gradually until reaching a 
plateau phase. On the contrary, the non-specific drugs have a dose-dependent 
action: increasing the dose, there will be an increase of cell death. 
 
Figure 1: Cell cycle 
 
According to their mechanism of action, there is a further division of anticancer drugs: 
 Drugs interfering with the functions of DNA cause direct damage to DNA itself 
(genotoxic agents) by forming an irreversible chemical bond or complexes with 
different stability. These processes alter the double helix conformation and 
functionality. 
Other compounds instead, induce indirect damage to DNA by inhibiting 
biosynthesis of nucleic acids (antimetabolites);  
 Drugs, interfering with cell division, are generally inhibitors of mitosis, that affect 
microtubule dynamics with consequent stabilization or inhibition of tubulin 
polymerization, and topoisomerases inhibitors. 
Chemotherapy drugs can’t tell the difference between reproducing cells of normal 
tissues (like those replacing worn-out normal cells) and cancer cells, particularly in 
rapid growth tissues, such as sex glands, hematopoietic tissue and mucous 
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membranes. This means that normal cells are damaged along with the cancer 
cells, and this causes side effects.  
Each time chemotherapy is given, it involves trying to find a balance between destroying 
the cancer cells (in order to cure or control the disease) and sparing the normal cells (to 
lessen unwanted side effects). Moreover, these drugs decrease the body's endogenous 
defense capacities and expose the patient to a higher risk of contracting infectious 
diseases. 
The main classes of drugs used in anticancer therapy are: 
 Alkylating agents - they directly damage DNA to keep the cell from reproducing. 
These drugs work in all phases of cell cycle and are used to treat many different 
cancers, including leukemia, lymphoma, Hodgkin disease, multiple myeloma, and 
sarcoma, as well as cancers of the lung, breast, and ovary. Specifically, these kind 
of drugs acts by alkylating nucleophilic sites of cellular macromolecules, also DNA, 
and this leads to the formation of inter- and intra-filament cross-links. Alkylating 
agents are divided into different classes, including Nitrogen mustards, 
Nitrosoureas, Alkyl sulfonates and Triazines.   
The general mechanism of action includes either intra-molecular cyclization to form the 
aziridinium ion (for those compounds having a bis(chloroethyl)amino or ethylenamino 
functional group) or the formation of a vinyl carbocation (for those compounds having a 
nitrous-ureic functional group); in both cases, a transfer of an alkyl group to a cellular 
constituent occurs. The main site for the alkylation of DNA is the N7 position of guanine, 
although other positions may be involved, as well as other nitrogenous bases and oxygens 
of the phosphate group (Figure 2). [3] 
 
Figure 2: Guanine 
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 Antimetabolites - interfere with DNA and RNA growth by substituting for the 
normal building blocks of RNA and DNA. These agents damage cells through the S 
phase, during cell chromosomes copying. They are commonly used to treat 
leukemias, cancers of the breast, ovary, and intestinal tract, as well as other types 
of cancer.  
 Topoisomerase inhibitors - chemotherapy drugs interfering with the action of 
topoisomerase enzymes (topoisomerase I and II). During the process of chemo 
treatments, topoisomerase enzymes control the manipulation of the structure of 
DNA necessary for replication. 
 Mitotic inhibitors - are often plant alkaloids and other compounds derived from 
natural products. They work by stopping mitosis in the M phase of the cell cycle, 
but can damage cells in all phases. 
 Intercalating agents – they insert their planar portion between two 
complementary base pairs of the DNA double helix, deforming and unwinding it. 
 Groove binders - chemical compounds containing a side chain (generally 
oligopeptide) with the ability of binding the major or the minor groove of DNA; 
 Strand breakers - they generate radical species that react with the sugar portion 
of DNA, resulting in the breakage of the polynucleotide filament.  
Among the classes of compounds mentioned, only the alkylating agents, intercalating 
agents, groove binders, and strand breakers act by interacting directly with DNA. 
Intercalators and groove binders bind to DNA through non-covalent bonds and therefore 
in a reversible manner, whereas alkylating agents and strand breakers act as irreversible 
inhibitors.  
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2. Topoisomerases 
DNA topoisomerases (Top) exist in all living organism. They are essential enzymes, as they 
induce DNA modification required during cellular processes such as replication, 
transcription, and repair. [4] 
The critical actions of Top are evident when referring to processes such as separation of 
DNA strands, essential for transcription and replication, the flawless segregation of two 
identical copies of entire genomes in two daughter cells following replication, and the 
formidable genomic compaction in cells. In particular, these enzymes are required to 
avoid super-helical tension and knots, in order to maintain the DNA compacted into a 
nucleus with a 6 µm diameter. Indeed, local relaxation of nucleic acids is required for 
transcription, replication and proper chromosomal segregation. These vital cellular 
processes generate torsional stresses, in the form of supercoiling, as well as DNA and RNA 
entanglements that are resolved by Top: positive supercoling rapidly stalls replication and 
transcription, and negative supercoling favours the formation of abnormal DNA structures 
like D loops, R loops, guanosine quartets and Z-DNA, all of which interfere with normal 
DNA metabolism.  Top are ubiquitos and essential. The human genome encodes six Top, 
whereas Escherichia coli only four. 
There are two major families of Top: type I (Top1) and type II (Top2), depending on 
whether they cleave only one or two DNA strands: Top1 cleave one DNA strand at a time 
and Top2 both strands, to perform their catalytic functions. Top1 is further subdivided 
into Top IA and IB, and Top2 also falls into two subclasses, IIA and IIB, but only the IIA 
type is human; only recently type IIB has been discovered in a particular bacterial strain.  
 
 
Figure 3: Classes of topoisomerases 
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Despite these differences, all Top cleave the DNA phosphodiester backbone by 
nucleophilic attack from a catalytic tyrosine residue, which becomes linked to the 
phosphate end (P-Y) of the DNA break. Those reactions are highly reversible and leave the 
DNA sequence unchanged following topoisomerization. 
 
 
Figure 4: (C) Noncovalent binding of type IB enzymes; (D) Scheme of the 3’-phosphotyrosine covalent bond 
in the Top1cc; (E) Trapping out the cleavage complex by CPT and the Top1 inhibitors; (F) Noncovalent 
binding of type IIA enzyme homodimers; (G) Scheme of the 5’-phosphotyrosine covalent bond in the 
Top2cc; (H) Trapping the cleavage complex by etoposide, doxorubicin or quinolones. 
 
E. coli type IA Top was the first Top discovered, and was initially named “ω protein” (for 
purification by ultracentrifugation that uses ω as a parameter of angular velocity). 
Eukaryotic Top1 is classified as type IB because of two differences with E. coli Top I: (i) it 
relaxes both negative and positive supercoils, whereas E. coli Top I only relaxes negative 
ones; (ii) it cleaves DNA by forming a tyrosyl-DNA covalent catalytic intermediate at the 
3’-end of the break (3’-P-Y; Figure 4D), while E. coli Top I forms a 5’-P-Y- intermediate. 
Eukaryotic type IA, named Top3, was identified through genomic homology search. 
Vertebrates encode two Top3 enzymes (Top3α and β). The last discovered human Top is 
Top1mt, a type IB enzyme, encoded in the nuclear genome but operate on mitochondrial 
13 
 
DNA (Figure 3A). In vertebrates, only Top1 and Top1mt form covalent linkages to the 3’-
end of the breaks (Figure 3A). All the other Top form 5’-phosphotyrosyl covalent bonds [5]. 
Bacteria tend to have a simpler organization than vertebrates, with only four Top in E. coli 
(Figure 3B). However, bacteria have two type IA enzymes (Top I and Top III) and two type 
IIA enzymes (gyrase and Top IV). 
 
2.1 Topoisomerase 1 
Based on conservation of sequence, sensitivity to limited proteolysis, hydrodynamic 
properties, and fragment reconstitution experiments, the 91-kDa human Top 1 protein 
has been subdivided into four distinct domains that comprises an N-terminal domain 
(open box), a core domain (gray box), a linker domain (diagonally striped box), and a C-
terminal domain (black box), as shown in Figure 5. The domain boundaries are based on 
sequence alignments, limited proteolysis studies, and the crystal structures of the 
protein. Domains essential for catalytic activity are the core and the C-terminal domains, 
the latter containing the catalytic tyrosine, while the other two are not indispensable. [6] 
 
 
Figure 5: Domain structure of human Top1. 
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Figure 6: Two views of the structure of human Top1. The structure of the enzyme (pdb entry 1A36) is 
viewed from the side with the DNA axis horizontally oriented (a) and looking down the axis of the DNA (b). 
Core subdomains I (residues 215–232 and 320–433), II (residues 233–319) and III (residues 434–633) are 
colored yellow, blue, and red, respectively. The linker (residues 641–712) and C-terminal domain (residues 
713–765) are shown in orange and green, respectively. In panel a, the amino terminus (N) and carboxyl 
terminus (C) of the protein are indicated, and the active site tyrosine is shown in black ball and stick. The 
long α-helix that connects the cap to the base of the core is labeled “Connector” in panel a. In panel b, the 
“Lips” region where the protein opens during DNA binding and unbinding is shown with opposing arrows, 
and the hinge region at the top of the connector helix is labeled “Putative hinge.” 
 
Top1 is found wrapped around the DNA in two distinct conformations: open and closed. 
In the compact or closed form, the enzyme exhibits a central pore, where the DNA is 
located. Inside the pore, there is the catalytic site of Top1, which is a highly conserved 
domain, consisting in the tyrosine 723 (responsible for nucleophilic attack to the 
phosphate of DNA, located in the C-terminal domain).  
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Activity of human Top1 involves four steps (Figure 7):  
1. DNA bond: the enzyme in the open conformation of its core domain recognizes the 
ribonucleotidic chain and leads to the subsequent formation of the non-covalent DNA-
topoisomerase complex, Top1cc; this bond culminates in the closure of Top around 
nucleic acid, so that the subdomains I and III of the core domain are touching;  
2. DNA cleavage: the amino acids of the active site are located in a position that prevent 
the nucleophilic attack by 723Tyr on phosphodiester bond of the DNA, to form a 
phosphotyrosinic bond and constitute the Top1 cleavage complexes;  
3. DNA relaxation: the enzyme undergoes a conformational change, which allows the 
passage of the intact filament through the interruption produced in the other one.  
4. DNA mending: it occurs by transesterification. Hydroxyl in 5’ end of cleaved strand 
attacks phosphate, aligned with the hydroxyl group itself, still bound to enzyme tyrosine 
within the complex Top1-Tyr-DNA. Thus, the original phosphodiester bond is 
reconstituted. Finally, the enzyme releases DNA [7,8].  
 
Figure 7: Topoisomerase I mechanism of action. 
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2.2 Topoisomerase 2 
Type II topoisomerases are required for the management of DNA superhelicity and 
chromosome segregation, and serve as frontline targets for a variety of small-molecule 
therapeutics. 
Top2 operate by a complex mechanism that involves the controlled association and 
dissociation of subunit dimerization elements. In this reaction, one DNA duplex (termed 
the “G-segment”) is bound and cleaved by the enzyme, while a second double-stranded 
DNA (the “T-segment”) is transported through the break. G-segment breakage is 
catalyzed by a pair of symmetrically related tyrosines forming a transient, but covalently 
linked, topoisomerase·DNA assembly termed “the cleavage complex”. Strand passage is 
typically dependent upon ATP, a cofactor that not only promotes T-segment capture and 
stimulates G-segment cleavage but also triggers the successive opening and closing of 
inter-protomer interfaces, or “gates”. 
 
 
 
Figure 8: Model relating DNA-gate status to C-gate dimerization and metal occupancy in the context of the 
type IIA topoisomerase reaction. Topoisomerase IIA dimers exist in an equilibrium between different 
combinations of associated or dissociated proteinaceous interfaces. Where double arrows are shown, the 
relative thickness of the arrows denotes the likely weighted distribution of the two states. Prior to DNA 
binding, DNA-gate closure can occur with either a closed (1) or an open (2) C-gate. G-segment binding 
promotes the TOPRIM domain, WHD, and tower domain of both protomers to clamp around the DNA (3); 
this event may promote C-gate opening (4). ATP binding and capture of a second duplex, the T-segment, 
promote cleavage of the G-segment (5), favoring C-gate closure. The T-segment exits through an open C-
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gate following its passage through the G-segment and resealing of the cleaved DNA (6). Binding of 
topoisomerase II poisons and inhibitors such as GSK299943 perturb the DNA-gate interface to a more 
extended rotation that is impaired for religation and may help maintain the C-gate in a closed conformation 
(7). Relative WHD displacements as observed between different ligand‐bound and/or free states are shown 
as cartoon cylinders and colored as per Fig. 5. The relative occupancies of the two metal-binding sites are 
also shown, with question marks denoting states that have yet to be imaged. The lone question mark 
associated with site A, state (4), reflects the fact that the DNAs found in these models lack a scissile 
phosphate and, hence, may not capable of binding a metal ion accordingly. 
Type IIA topoisomerases, which comprise one of two type II topoisomerase subfamilies 
found predominantly in bacteria and eukaryotes, possess three such regions, termed the 
N-gate, DNA-gate, and C-gate (Figure 9). 
 
 
Figure 9: Domain structure of human topoisomerase II; Crystallization constructs. Primary structure of 
human TOP2A. The region crystallized (residues 431–1193) is shown in color. Specific domains (TOPRIM, 
WHD, tower) and dimerization gates are labeled with important residues and features highlighted: catalytic 
tyrosine and associated arginine, RY; intercalating isoleucine, I; metal-binding triad, DxD and E.  
 
Topoisomerase II enzymes have the ability to cut both strands of a double-stranded DNA 
molecule, pass another portion of the duplex through the cut, and reseal the cut in a 
process that utilizes ATP. Depending on the DNA substrate, these maneuvers will have the 
effect of changing a positive supercoil into a negative supercoil or increasing the number 
of negative supercoils by 2. The Topo II enzymes from mammalian cells cannot, like E. coli 
DNA gyrase, increase the superhelical density at the expense of ATP; presumably, no such 
activity is required in eukaryotes, since binding of histones increases the potential 
superhelicity. All type II topoisomerases catalyze catenation and decatenation, that is, the 
linking and unlinking, of two different DNA duplexes (Figure 10). 
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Figure 10: Reactions catalyzed by topoisomerase II 
 
As regard the structure, Top2 is a dimer of two identical subunits and catalyzes a process 
similar to that of Top1. The mechanism of action (shown in figure 11), instead, is different 
from the enzymes of class I: initially, the enzyme binds one part of a DNA strand, the G 
segment (dark blue), inducing a conformational change in the B, B′, A, and A′ domains of 
the enzyme (2). After binding of ATP (indicated by the asterisks) and another part of the 
DNA strand, the T segment (light blue), a series of reactions occur in which the G segment 
is cut by the A and A′ domains (light orange) of the enzyme and the ends of the G DNA 
become covalently linked to tyrosine residues in these domains (3 and 3a) (Figure 11). 
Simultaneously, the ATP-binding domains (green) move toward each other, transporting 
the T segment through the break and into the central hole (4). The cut G segment is then 
resealed, and the T segment is released by a conformational change that separates the A 
and A′ domains at the bottom of the enzyme (5). The interface between the A and A′ 
domains then re-forms, a reaction that requires ATP hydrolysis and regenerates the 
starting state 2. At this point, the G segment can dissociate from the enzyme by 
conversion of 2 into 1 (Figure 11). Alternatively, the enzyme can proceed through another 
cycle, again passing the T segment through the G segment and thus removing two more 
supercoils. [9] 
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Figure 11: Schematic representation of the catalytic cycle for human Top2 enzymes 
 
An important characteristic of this enzyme is the requirement of Mg2+. Indeed, in 
presence of Mg2+, the tyrosine from each Top2 monomer attacks a DNA phosphodiester 
bond four bases apart on opposite strands of the G duplex and become covalently linked 
to the 5’ end of the broken DNA (Figure 12). 
 
 
Figure 12: proposed structure-based reaction mechanism for phosphodiester bond cleavage by TDP2 
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3. Topoisomerase inhibitors 
The Top enzymes have been researched as targets for the generation of new cancer 
treatments, because, when they are inhibited in a cell, the result is that the cell dies. 
Therefore, Top inhibitors have the ability to kill all cells undergoing DNA replication, 
reading of the DNA for protein production or experiencing repair of DNA damage. Since 
cancer cells divide much more rapidly than normal cells, the cancer cells will be killed by 
Top inhibitors, though some normal cells with Top activity will also be killed. 
The molecular mechanism of action of Top inhibitors, i.e. their specific binding at the 
interface of topoisomerase-DNA complexes, led to the interfacial inhibition concept 
(Figure 13). [10] 
 
 
 
Figure 13: Interfacial inhibition for Top1 (left) and Top2 inhibitors (right). Under normal conditions, Top1 
and Top2 cleave and religate DNA very rapidly (A–B and E–F). Religation is faster than cleavage and 
cleavage complexes are transient. Drugs (green) (C–D and G–H) bind reversibly (C and G) at the interface of 
the cleaved DNA and the enzyme by forming a ternary complex (see text for details). The pdb coordinates 
for D and H are 1T8I and 3QX3, respectively. 
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Top inhibitors are exquisitely selective and without ambiguity eligible as “targeted 
therapies”. Clinically relevant Top1 inhibitors do not affect Top2, and, conversely, Top2 
inhibitors do not trap Top1 enzymes. Furthermore, the inhibitors of bacterial 
topoisomerases (gyrase and Topo IV) are inactive against host cell topoisomerases (Top2 
and Top1), which accounts for their antibacterial potency without impact on the host 
genome. 
 
3.1 Top1 inhibitors 
Top1 inhibitors are a new class of anticancer agents with a mechanism of action aimed at 
interrupting DNA replication in cancer cells, the result of which is cell death. Most Top1 
inhibitors are derivatives of the plant extract camptothecin (Figure 14), which is the first 
inhibitor of Top1 discovered.  
Quinoline alkaloid camptothecin (CPT), isolated in 1958 from Chinese tree Camptotheca 
acuminate, is an important natural product serving as a lead compound for designing 
many more active and clinically useful anticancer drugs. Camptothecin derivatives are 
FDA-approved Top1-targeted anticancer drugs. The potent anticancer activity of these 
compounds was known for at least 20 years before the identification of Top1 as their 
molecular target. 
 
 
Figure 14: Camptothecin. 
 
The natural alkaloid CPT showed remarkable anticancer activity in clinical trials; it 
selectively inhibits DNA Top1, binding and stabilizing the Top1-DNA cleavage complexes 
(Top1cc). 
More specifically, the overall mechanism of enzymatic action involves four distinct steps 
(Figure 15): (1) DNA topoisomerase I binding; (2) breaking the single strand of DNA by 
reversible transesterification; (3) DNA relaxation by single-strand passage around the 
unbroken strand; and (4) religation of cleaved DNA and concomitant release of the 
enzyme. 
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CPT non-covalently stabilizes the cleavable complex of DNA topoisomerase I, preventing 
the subsequent religation step (in this context the enzyme itself is a DNA-damaging 
agent). Stabilization of the cleavable complex is not yet sufficient for the promotion of cell 
death mainly due to the complex reversibility. The lethal effect is a consequence of 
interaction between moving replication fork (or transcription process) and the CPT-
stabilized cleavable complex. This results in the formation of a double-strand break 
located at the fork and irreversible arrest of DNA replication in the S/G2 phase of cell 
cycle, leading to the apoptosis[11]. 
 
 
 
Figure 15: Schematic representation of mechanism of action of camptothecin. 
 
Four lines of evidence demonstrate the selective poisoning of Top1 by CPT: 
1. only the natural CPT isomer is active against Top1; 
2. genetically modified yeast deleted for Top1 is immune to CPT; 
3. cells selected for CPT resistance bring precise and casual point mutations in the 
Top1 gene; 
4. CPT-producing plants produce a point mutation in Top1 that also renders the 
enzyme immune to CPT. 
Despite its considerable activity and unique mechanism of action, CPT exhibits several 
undesired properties, which hampered its use in therapy. Firstly, CPT is very low water 
soluble, complicating administration of the drug. Another problem associated with parent 
CPT is the a-hydroxylactone ring (ring E) opening under physiological condition, leading to 
the carboxylate open form of CPT. The carboxylic acid or its sodium salt, although soluble, 
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has much lower anticancer potency as compared with CPT (Figure 16). Moreover, this 
ionic form preferentially binds to the human serum albumin (HSA), lowering the 
concentration of the accessible drug. High toxicity of CPT and its sodium salt (which 
resulted in suspension of its trials in the 1970s) adds to the unfavorable proﬁle of CPT. All 
of these drawbacks were addressed in an intense research activity for the last 30 years. 
This led eventually to deeper understanding of the structure–activity relationship (SAR), 
and resulted in the development of very active and soluble, semisynthetic anticancer 
drugs: Irinotecan, Topotecan and Belotecan, approved for clinical use (Figure 16). [12] 
 
 
Figure 16: Camptothecin and its clinical derivatives. 
 
Other derivatives like Gimatecan, Lurtotecan and Exatecan, which structure is shown in 
Figure 17, have been developed to improve solubility and clinical tolerability and allow 
oral administration. However, they retain the chemical instability of camptothecins.  
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Figure 17: Structures of some camptothecin derivatives. 
 
To overcome the problems encountered with the camptothecins, in particular the E ring 
instability, two different approaches have been taken: 
- The first involves the addition of a methylene group in the E ring, as in the 
homocamptothecins (like Diflomotecan). This change limits E ring opening, but 
once it happens, they become irreversibly converted to an inactive carboxylate. 
 
 
Figure 18: Synthetic E-ring-modified camptothecin derivative: Diflomotecan 
- The second approach is the conversion of the E ring to a five-membered ring, 
which completely stabilizes the drug. These compounds, exemplified by S39625, 
are highly potent synthetic compounds against Top1. 
 
N
N
O
O
O
O
OH
A B
E
 
Figure 19: Synthetic E-ring-modified camptothecin derivative: S39625 
 
In addition to compounds derived from CPT, other derivatives with a different structure 
were also synthesized.  
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The first reaching clinical trials was edotecarin (Figure 20). However, like other 
indolocarbazoles, it affects other cellular targets besides Top1, including DNA itself.  
Two families of nonCPT Top1 inhibitors are entering clinical development: the 
indenoisoquinolines and the dibenzonaphthyridinones (Figure 20). Both are synthetic and 
chemically stable, thereby overcoming the E-ring-opening inactivation of CPTs. They also 
overcome the drug efflux-associated resistance of CPTs and produce more stable cleavage 
complexes at different genomic locations compared to CPTs.  
The aromathecins (Figure 20) are at an earlier stage of development [5]. 
 
 
Figure 20: Synthetic E-ring-modified non-camptothecins derivatives. 
 
3.2 Top2 inhibitors 
Compounds that target type II Topoisomerase are split into two main classes: Top2 
poisons, which target the topoisomerase-DNA complex, and Top2 inhibitors, which 
disrupt catalytic turnover. [13] 
Many Top2 poisons have demonstrated anti-cancer activity. Top2 poisons can be further 
sub-divided into intercalating and non-intercalating poisons.                                                 
The intercalators are chemically diverse, and include doxorubicin and other 
anthracyclines, mitoxantrone, and a variety of other compounds that are not currently in 
clinical use, such as amonafide and ellipticine (Figure 21) Other than their ability to 
intercalate in DNA, there is no obvious chemical similarity that could explain the ability of 
these compounds to trap Top2. Importantly, some compounds, such as ethidium 
bromide, have little ability to poison Top2, suggesting that intercalation of a small 
molecule is insufficient to trap Top2 as a covalent complex on DNA. Some of the 
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intercalating Top2 targeting drugs, notably the anthracyclines, produce a variety of 
effects on cells, including many effects that are independent of their action against Top2.  
 
 
Figure 21: Topoisomerase 2 inhibitors. 
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For example, doxorubicin is known to produce free radicals, to cause membrane damage, 
and to induce protein/DNA crosslinks. Whether Top2 is the most important target of 
anthracyclines remains a controversial issue, although some of the results support the 
hypothesis that Top2 is the most relevant target for both clinical response and 
cardiotoxicity. 
Non-intercalating Top2 poisons include the epipodophyllotoxin etoposide and teniposide, 
and fluoroquinolones, which are mainly active against prokaryotic type II topoisomerases 
(Figure 21). Since non-intercalating Top2 poisons do not interact strongly with DNA, it has 
been suggested that protein drug interactions play key roles in their ability to trap Top2 
covalent complexes. Several classes of compounds have been described that inhibit Top2 
activity, but do not increase DNA cleavage. Most prominent are the bisdioxopiperazines, 
which non-competitively inhibit the enzyme ATPase activity and trap Top2 as a closed 
clamp. ICRF-187, a bisdioxopiperazine, is used as a cardioprotectant in some patients 
treated with anthracyclines. Other Top2 catalytic inhibitors include novobiocin, 
merbarone, and the anthracycline aclarubicin. All these last three compounds have 
significant targets besides Top2; therefore, these compounds have not been useful in 
assessing the feasibility of using catalytic inhibitors of Top2 as anti-cancer therapy. 
Merbarone has attracted interest because it is the only agent that has been found to 
inhibit Top2 cleavage of DNA withouth affecting the protein. QAP1 is a newly described 
purine analog that was rationally designed to target the Top2 ATPase activity. This 
compound may be particularly useful in assessing the effects of catalytic inhibition of 
Top2. Several other catalytic inhibitors have been described; however, their detailed 
mechanism of action has not been explored. 
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4. Tyrosyl-DNA phosphodiesterase (TDP) 
 
Tyrosyl-DNA phosphodiesterases (TDP1 and TDP2) are among the most recently 
discovered DNA repair enzymes. Ongoing studies point to their relevance for the repair of 
trapped topoisomerase-DNA complexes and processing of diverse 3′- and 5′-blocking 
groups at DNA ends.  
Top1 is required for both normal and cancer cells, and intrinsic defects in DNA repair and 
checkpoints, which are the landmarks of cancer cells, are likely the Achilles’ heels of 
cancer cells treated with anti-Top1 drugs. Drug-stabilized Top1cc are converted into DNA 
damage by two main processes: DNA replication and transcription. Collision of DNA or 
RNA polymerase complexes into stalled Top1cc disrupts the architecture of the Top1cc, as 
shown in Figure 22. 
 
Figure 22: Conversion of Top1 cleavage complexes into DNA damage by displacement of the 5’-hydroxyl at 
the end of the cleaved strand by DNA replication, transcription, or preexisting DNA lesions. (A) Schematic 
representation of a Top1 cleavage complex trapped by camptothecin (black rectangle). Top1 is covalently 
bound to the 3’-end of the broken DNA. The other end is a 5’-hydroxyl. (B) Conversion of the cleavage 
complex into a covalent Top1–DNA complex by a colliding transcription complex (the RNA is shown in 
green). (C) Conversion of the cleavage complex on the leading strand into a covalent Top1–DNA complex by 
a colliding replication fork (the leading replication is shown in red; the lagging replication in blue). (D and E) 
Formation of a suicide complex by a single-strand break on the same (D) or the opposite (E) strand from the 
Top1 scissile strand. (F) Formation of an irreversible Top1cc by a base lesion ((∗) abasic site, mismatch, 
oxidized base) at the 5’-end of the cleavage site. (G) Formation of a double-strand break at two Top1 
cleavage sites close to each other. 
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The double-strand end generated by the stalled polymerase cannot reverse the tyrosine-
phosphodiester bond and thereby generates an irreversible Top1-DNA crosslink 
associated with a double-strand end. The various lesions resulting from the conversion of 
reversible Top1cc into DNA damage are sometimes referred to as “suicide complexes” or 
“dead-end covalent complexes”. The repair of such lesions is only partially understood. At 
least two steps need to take place: removal of the Top1 from the 3’-DNA end and 
religation of the free 5’-end [8].The best-characterized pathway for the removal of Top1-
DNA adducts implicates tyrosyl-DNA phosphodiesterase 1. 
 
4.1 Tyrosyl-DNA phosphodiesterase 1 (TDP1) 
Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that belongs to the superfamily of 
phospholipase D, which includes a highly diverse group of proteins involved in 
phospholipid metabolism. Mainly, its function is to catalyze the hydrolysis of a 
phosphodiester bond between a tyrosine residue and a DNA 3′-phosphate. [14] 
Structurally, human TDP1 is a 68-kDa polypeptide comprising 608 amino acid residues 
and consist of two domains (Figure 23). The N-terminus domain is dispensable for 
enzymatic activity, but regulates TDP1 recruitment and protein stability, whereas the C-
terminus catalytic domain belongs to the phospholipase D family (PLD) as it contains two 
catalytic HKN motifs separated from each other by 210 amino acids residues. One aspect 
that differentiates TDP1 from other PLD family members is the replacement of aspartates 
in the HKD motifs with asparagines (HKN motifs). 
TDP1 acts as a monomer with the two HKN motifs in close proximity to form the catalytic 
site located inside an asymmetric substrate-binding channel, which is relatively limited 
and positively charged to bind the single-stranded DNA substrate. Both HKN motifs 
stabilize the vanadate used as transition intermediate by six H-bonds between the 
nitrogen atoms of the HKN residues and the oxygen atoms of the vanadate.  
The active site asparagine residues (N283 and N516) stabilize the neighboring lysine side 
chain by hydrogen bonding between their side chain oxygen atoms and the ε-amino 
groups of the lysines. The single-stranded DNA substrate is held in place by a network of 
polar interactions involving the 5’-phosphate groups of the 3 nucleotides upstream from 
the phosphotyrosine bond (Figure 23). 
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Figure 23: Crystal structure of TDP1. (A) Ribbon representation of TDP1 polypeptides. N-terminal (white) 
segments (residues 1-148) are absent in the crystal structure shown below. Conserved catalytic segments 
are highlighted in yellow. (C) Surface representation of the crystal structure for TDP1. Proteins are 
represented in light pink, catalytic residues in yellow, DNA in blue sticks, peptide in green sticks and both 
sticks colored by element (N, blue; O, red; P, orange; Vanadate, grey). (E) Detailed contacts between 
substrates and TDP1 residues in the catalytic site. Catalytic residues are represented as yellow sticks; 
residues involved in polar interactions are in cyan sticks; residues involved in hydrophobic interactions in 
magenta sticks. All sticks are colored by element (N, blue; O, red; P, orange; Vanadate, grey). Dashed lines 
highlight polar interactions. 
 
The most important residues involved in this stabilization include S400, S403, K469, S518, 
K519 and A520. The residues that are engaged in hydrophobic interactions with DNA are 
F259, P461 and W590. 
As TDP1 cleavage complexes form at many different genomic sites, and TDP1 need to be 
effective irrespective of the DNA sequence environment, the TDP1 DNA substrate 
recognition is not restricted to basic particular sequences; indeed, substrate stabilization 
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is made via either hydrofobic or polar interactions with the DNA phosphodiester 
backbone. [15] 
Instead, as it regards the TDP1 catalytic mechanism, it does not require nucleotide 
cofactor or metal, but it is relatively complex: it consists of two-step with a transient 
covalent intermediate. As shown in figure 24, the first step consist in a nucleophilic attack 
of the Top1-DNA phosphotyrosil bond by H263 residue from the N-terminal HKN motif. 
The H493 residue from the opposite HKN motif acts as a general acid and donates a 
proton to the tyrosine-containing peptide-leaving group. A transient covalent 
phosphoamide bond is formed between H263 and the 3′-end of the substrate. The 
opposite H493 residue acts as a general base and hydrolyzes this covalent intermediate 
via an activated water molecule. This generates a product with a 3′-phosphate end, which 
needs to be further processes by polynucleotide kinase phosphatase (PNKP). [16] 
 
 
Figure 24: TDP1 catalytic cycle. (A) Nucleophilic attack of the phosphodiester backbone by the imidazole N2 
atom of H263. H493 donates a proton to the tyrosyl moiety of the leaving group. (B) Phosphohistidine 
covalent intermediate. (C) Second nucleophilic attack via an activated water molecule by H493. (D): 
Generation of a final 3′-phosphate product and freeTDP1. (E) The SCAN-1 mutations (H493R) leads to an 
accumulation of the Tdp1-DNA intermediate and a defect in TDP1 turn- over rate. 
 
 
Recent studies has shown that a mutation of the catalytic histidine to an arginine residue 
at position 493 results in the accumulation of covalent TDP1-DNA intermediates, 
ultimately leading to a rare autosomal recessive neurodegenerative disease called 
spinocerebellar ataxia with axonal neuropathy. 
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The requirements for a high TDP1 activitiy are: 
1. a DNA segment consisting of at least a few nucleotides that would bind in TDP1’s 
positively charge groove; 
2. an exposed phosphotyrosyl bond at the TDP1-DNA junction: TDP1 acts after the 
5’-end of the broken DNA has been digested or displaced to provide access to 
the 3’-phosphotyrosyl bond; 
3. a short Top1 polypeptide segment; TDP1 activity, in fact, decreases as the length 
of Top1 chain is extended. Besides, Top1 needs to be proteolysed for efficient 
TDP1 activity.  
For all these reasons, the development of inhibitors of TDP1 may be useful in combined 
drug therapy with CPTs for the treatment of cancers, since TDP1 theoretically counteracts 
the effects of CPT and its derivatives. 
In addition to TDP1, there are other mechanisms to removal of Top1cc. In fact, there are 
at least three endonuclease complexes that can cleave 3’-damaged DNA from DNA 
lesions. [17] 
 
Figure 25: Repair of Top1 covalent complexes by the 3-endonuclease pathways. (A) Schematic 
representation of the genetic pathways implicated in the removal of the Top1-DNA covalent complexes. (B) 
Differential substrate requirements for Rad1/Rad10, Mre11/Rad50, and Mus81/Mms4 (budding yeast 
ortholog of human and fission yeast Mus81/Eme1). Both Rad1/Rad10 and Mre11/Rad50 require the DNA to 
be single-stranded opposite to the 3’-flap, suggesting that gap repair should follow their action. By contrast, 
Mus81/Mms4 requires the DNA to be double-stranded opposite to the 3’-flap as in collapsed replication 
forks. 
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Among these, we find Rad1/Rad10 that appear to function in parallel with TDP1/PNKP. 
Whereas Mus81/Mms4, Mre11/Rad50/Xrs2, and Rad27 functions in parallel. 
Like TDP1, Rad1/Rad10 requires a single-stranded gap between the 3’-end to be 
processed and the 5’-end of the DNA, suggesting that TDP1 and Rad1/Rad10 share 
common substrates. [18] 
The Mre11/Rad50/Xrs2 (MRX) complex preferentially cleaves gapped substrates and 
hairpin structures. However, the MRN complex also possesses checkpoint functions that 
probably contribute to the normal response to CPT. 
Mus81/Mms4 preferentially cleaves broken replication forks and requires the presence of 
duplex DNA near the 3’-end to be processed. Mus81-deficient yeasts are highly sensitive 
to CCPT [8,18].  
The Top1-induced double-strand break (DSB) generated by replication fork collisions can 
be processed both by homologous recombination (Rad51/52) and non-homologous end-
joining (NHEJ). Figure 26[8] shows two possible pathways for the repair and restart of 
replication forks following Top1-induced DNA damage. In panel (A), TDP1 or Mus81/Eme1 
would remove the Top1cc. The repair of the DSB proceeds by homologous recombination 
following 5’-end resection. The resulting 3’-single-stranded DNA segment serves to 
initiate homologous recombination (HR) by the Rad51/Rad52 pathway. 
In panel (B), the other pathway is shown, initiating by replication fork regression (RFR) [19]. 
During RFR, annealing of the newly replicated leading and lagging strands forms a DNA 
cruciform (four stranded junction, referred to as “chickenfoot”)[20]. Once the DNA 
downstream from the Top1cc has been reannealed, the Top1 cleavage complex could 
reverse without intervention of repair enzymes since the 5’-hydroxyl end of the DNA 
could be aligned with the Top1-DNA phosphotyrosil bond. 
When these alternative pathways are inactivated, cells most likely rely more on the TDP1 
dependent pathway for repairing CPT-induced DNA damage. Since many cancer cells are 
deficient in one or more DNA damage repair pathways, inhibiting TDP1-dependent 
pathway have the potential to selectively sensitize cancer cells over normal cells to Top1 
poisons. 
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Figure 26: Schematic representation of the proposed repair of Top1-mediated DNA replication induced 
DSBs. (A) The Top1–DNA covalent complex is removed and the lagging strand ligated to restore one duplex. 
The 5’-end is first digested, leading to the formation of a 3’-single-stranded DNA segment that can act as a 
substrate for homologous recombination. (B) Replication fork regression allows the normal religation of the 
Top1 cleavage complex and lead to the formation of a “chicken foot”, which is equivalent of a Holliday 
junction. Replication fork restart requires melting of the “chicken foot” or resolution of the corresponding 
Holliday junction by the RecQ helicase/Top3 pathway. 
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4.2. Tyrosyl-DNA phosphodiesterase 2 (TDP2) 
Tyrosyl DNA phosphodiesterase 2 (TDP2) is a DNA repair enzyme with several functions; it 
seems to be involved in DNA repair, viral replication and potentially oncogenesis. 
Originally, it was designated as TRAF and TNF receptor associated protein (TTRAP), and 
ETS1-associated protein II (EAPII); indeed, it was identified as an intracellular tumor 
necrosis factor (TNF) receptor binding protein, because it was shown to interact with the 
TNF receptor-associated factors TRAF, in particular with TRAF6. Subsequent analyses on 
peptide sequences suggested the DNA enzymatic function of TDP2, yet was demonstrated 
his enzymatic function for Top2 repair. Recently, it was revealed as a (and the first) 
human 5’-tyrosyl DNA phosphodiesterase; it plays a critical role for the repair of 
topoisomerase II (Top2) cleavage complexes (Top2cc) and encodes an enzyme that 
hydrolyzes 5’-tyrosine-DNA adducts that mimic abortive Top2cc. Recent studies have 
shown that TDP2 also promotes cell death induced by TGF-β, suggesting a potential role 
as modulator between pro-survival and pro-apoptotic signaling by TGF-β.  
 
 
Figure 27: Crystal structure of TDP2. (B) Ribbon representation of TDP1 polypeptides. N-terminal (white) 
segments (residues 1-120) are absent in the crystal structure shown below. UBA: ubiquitin binding 
associated domain. Conserved catalytic segments are highlighted in yellow. (D) Surface representation of 
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the crystal structure for TDP1. Proteins are represented in light pink, catalytic residues in yellow, DNA in 
blue sticks, peptide in green sticks and both sticks colored by element (N, blue; O, red; P, orange; Vanadate, 
grey). Magnesium is represented as the green sphere. (F) Detailed contacts between substrates and TDP2 
residues in the catalytic site. Catalytic residues are represented as yellow sticks; residues involved in polar 
interactions are in cyan sticks; residues involved in hydrophobic interactions in magenta sticks. All sticks are 
colored by element (N, blue; O, red; P, orange; Vanadate, grey). Dashed lines highlight polar interactions. 
 
TDP2 has shown several functions: it can remove a variety of covalent adducts from DNA 
through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5'-
phosphate; it catalyzes the hydrolysis of dead-end complexes between DNA and the Top2 
active site tyrosine residue; moreover, it hydrolyzes 5'-phosphoglycolates on protruding 
5' ends on DNA double-strand breaks (DSBs) due to DNA damage by radiation and free 
radicals.  
TDP2 was discovered as a human tyrosyl DNA phosphodiesterase that specifically cleaves 
off tyrosine from the 5’-end of DNA, leaving a phosphate group ready for relegation.  
The 5’-tyrosyl-DNA phosphodiesterase activity of TDP2 and its function in repairing 
trapped Top2 cleavage complexes suggest the importance of TDP2 as a target for 
anticancer therapy. However, it was recently shown that TDP2 is up-regulated in p53 
mutant tumor cells. 
Although TDP2 registers increased activity for 5'-phospho tyrosine residues, it can also 
process 3'-tyrosyl moiety substrates, albeit with much lower affinity. 
Recent studies have shown that TDP2 prefers DNA substrates with single-stranded 
characteristics on the 5’-end. This is consistent with the fact that Top2 generates cleaved 
DNA molecules with 4-base overhangs on the 5’-ends.  
As regards the mechanism of action, shown in figure 28, it is believed that Top2-derived 
peptide (trapped topoisomerase) linked to 5′-DNA via a phosphotyrosyl bond (A). (B) 
Upon binding of the covalent peptide-DNA substrate in the Tdp2 active site, two 
magnesium ions are coordinated by the TDP2 catalytic residues for nucleophilic attack of 
the phosphotyrosyl bond (black arrows). (C) Cleavage products consisting in the 
topoisomerase polypeptide (top) and the liberated DNA with a 5′-phosphate end (Figure 
28). 
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Figure 28: Proposed reaction mechanism for phosphodiester bond cleavage by TDP2. 
 
Test with substrates of different lengths, all sharing the same DNA sequence in the 
proximity of the 5'-tyrosine, showed that TDP2 processed all substrates, but it is more 
efficient with the longer substrates, suggesting its binding to single-stranded DNA. 
The enzyme can also process an oligonucleotide substrate as short as 5 nucleotide, so it’s 
not required a long DNA fragment for TDP2 recognition. TDP2 only recognizes the bulky 
adduct attached to a tyrosine but not those directly attached to DNA and cleaves from 
the phospho-tyrosine bond. Moreover, TDP2 is not only specific but also efficient in 
recognizing and processing trapped cleavage complexes even in the form of a longer 
peptide. 
An important difference between TDP2 and TDP1 is that TDP1 functions without metal 
cofactor and utilizes a transient covalent intermediate.  
Another peculiarity of TDP2, is the requirement of metal ions for the 5'-
phosphodiesterase activity. In fact, TDP2 is inactive in the absence of divalent metal, 
whereas its activity is maximal in the presence of Mg2+ and Co2+. Mn2+ is also an effective 
cofactor, while Ca2+ or Zn2+ enabled less than 50% of the activity. Further studies suggest 
that TDP2 activity is robust under varied conditions, including broad pH range and low 
Mg2+ and  Mn2+ concentrations (Figure 29). 
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Figure 29: Metal selectivity of human recombinant TDP2. TDP2 processing activity in the presence of mixed 
metals is shown. 5’-Tyrosyl-DNA phosphodiesterase activity of TDP2 was assayed in the presence of varying 
concentrations of Mg
2+
 in the absence or presence of Ca
2+
. 
 
TDP2 utilizes a two metal mechanism for catalysis, with two metal binding site: the metal 
A binding site is coordinated by Asp-262, His-351, and possibly Asn-264. The metal ion at 
site A would also coordinate a deprotonated water molecule for nuclephilic attack, 
assuming the orientation of DNA binding site in the same between APE1 and TDP2. Metal 
B, instead, is coordinated by the carboxylates of Asp-122 and Glu-152. On the contrary of 
having one acidic residue directly coordinating both metal ions, Asn-120 may indirectly 
bridge the two metal binding site by hydrogen bonding to Glu-152 and Asp-262 (Figure 
30). 
 
Figure 30: Proposed structure-based reaction mechanism for phosphodiester bond cleavage by TDP2. 
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In addition, TDP2 has an active profile from pH 7.5 to 10, indicating that the protonation 
states of the key residues in the active site are unperturbed in this range. 
As regards TDP2 structure, it is smaller than TDP1, with a molecular mass of 41 kDa; like 
TDP1, it is a two-domain protein with the catalytic domain in the C-terminus, while its N-
terminal domain supports an ubiquitin-associated domain. Because TDP2 has been 
related to the cation-dependent endonuclease family, the amino acid sequences of TDP1, 
APE1 and exonuclease III were aligned, that shows that TDP2 contains all four conserved 
catalytic motifs (TWN, LQE, GDXN and SDH) that are characteristic of these nucleases and 
critical for TDP2 phosphodiesterase activity; in particular, Asn-120, Glu-152, Asp-262 and 
His-351 form the catalytic sites of TDP2.  
Comparing the structure of the three endonucleases, it was shown that TDP2 shares 30% 
sequence similarity with exonuclease III and 14% sequence identity with APE1 (Figure 31 
and 32). 
 
 
Figure 31: Proposed structure of human TDP2 based on the I-Tasser program and sequence alignment with 
human APE1 and Thermophilic exonuclease III. 
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Figure 32: Alignment of humanTDP2, APE1 and thermophilic exonuclease III amino acid sequences.  
 
Finally, TDP2 was recently identified as the host VPg unlinkase for a large family of 
viruses, picornaviruses. Its activity is vital for viral replication as the 5’-end of the viral 
genomic RNA by the 5’-phosphotyrosil activity of TDP2, thus allowing translation of virus-
encoded proteins. Picornavirues family comprises many pathogens responsible for 
diseases in human and animals, consequently, inhibitors of TDP2 may serve as treatments 
for vast population exposed to these diseases. 
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5. TDP inhibitors 
5.1 TDP1 inhibitors 
Mechanistic studies of TDP1 activity have been enormously important in guiding the 
search for effective TDP1 inhibitors. As a member of phospholipase D (PLD) superfamily, 
TDP1 has two conserved HKD motifs located on different domains but clustering together 
in tertiary arrangement to form an active site27. These two HKD motifs are responsible 
for two sequential hydrophilic attacks on the phosphodiester bond at the active site). 
TDP1 can act on DNA substrates linked to a wide-range of 3′-blocking lesions via a 
phosphodiester linkage (Figure 33). [21] 
The known TDP1inhibitors are the following: 
 Aminoglycoside Antibiotics. Because TDP1 belongs to the PLD superfamily, known 
inhibitors for the other members of the family, such as neomycin, were tested for 
TDP1 inhibitory activity. Using TDP1 biochemical assays, it was found that 
millimolar concentrations of neomycin inhibits purified recombinant TDP1; the 
two neomycin analogs, paromomycin and lividomycin, also inhibited TDP1 activity 
at slightly higher concentrations (Figure 34) [22]. 
 
Figure 33: Chemical structures of aminoglycoside antibiotics. 
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Figure 34: A) Scheme of the domain structure of human Tdp1. The N-terminal and C-terminal domains 
correspond to residues 1-350 and 351-608, respectively. Positions of the “HKN” motifs and phosphorylation 
site (serine 81) are shown in black, with the position of the SCAN1 mutation (H493) shown in italics. B) 
Crystal structure of the quaternary complex consisting of truncated Tdp1 (Δ1-148), vanadate, a Top1 
peptide, and single-strand DNA (PDB:1NOP). Shown as surface models, the N-terminal and C-terminal 
domains of Tdp1 are in light brown and gray, respectively [see (A)]. Shown in stick structures is the 
substrate transition-state mimic consisting of single-strand DNA in green, vanadate in magenta, and the 
peptide in blue. C) The active site residues of Tdp1 are shown in stick structures with the rest of the protein 
shown in ribbon diagram; the domain colors correspond to those shown in (A) and (B). The substrate 
transition-state mimic structures are in the same colors as in (B), seen here from the bottom of the binding 
cleft projecting outwards. For clarity, two loops in the N-terminal domain have been removed from the 
view. D) Proposed two-step catalytic mechanism of human Tdp1. (1) In the first step, His263 acts as a 
nucleophile, attacking the phosphorus atom in the phosphodiester bond between the 3′-lesion and the DNA 
3′-oxygen. His493 donates a proton to the leaving group (HO-R). (2) A Tdp1-DNA intermediate forms 
wherein His263 is attached covalently to the 3′-end of the DNA via a phosphoamide bond. (3) A second 
nucleophilic attack by a water molecule activated by His493 hydrolyzes the phosphohistidine intermediate 
(4) The Tdp1 active site is regenerated and the 3′-phosphate DNA end is released. 
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 Furamidine is a compound that inhibits TDP1 at low micromolar concentrations 
(Figure 35). It is known to bind to duplex DNA in the minor groove selectively at 
AT-rich sites, as well as intercalating between GC base pairs. Further investigation 
revealed that furamidine binds not only to DNA duplex, but also to single-stranded 
DNA, and similar analysis also showed that furamidine interacts with TDP1. These 
results raised the possibility of an inhibitory mode of action by combined 
interaction to the DNA substrate and to TDP1, which is reminiscent of the 
interfacial inhibition of Top1cc by Top1 inhibitors.  
Other diamidine compounds, berenil and pentamidine (Figure 35), are much less 
effective than furamidine at inhibiting TDP1. Both compounds share the overall 
curved structure of furamidine, but substitute the furan ring linker in furamidine 
with other linking groups. This suggests that the furan linker is important for TDP1 
inhibitory activity, potentially by directly interacting with the DNA or TDP1 or 
both, or by stabilizing the overall curvature of the compound. [25] 
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Figure 35: Chemical structures of berenil, furamidine and pentamidine. 
 
 Tetracyclines. A number of tetracycline compounds, including rolitetracycline 
(Figure 36) were identified as positive hits in two separate high-throughput 
screens for TDP1 inhibitors. The preliminary results on tetracyclines showed 
micromolar inhibitory effect against TDP1 but lacked apparent structure-activity 
relationship. Nevertheless, these compounds potentially warrant further 
investigation. 
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Figure 36: Chemical structure of rolitetracycline. 
 
 Phosphotyrosine Mimetics. The strongest TDP1 inhibitors identified to date are 
TDP1 phosphotyrosine substrate mimetics. Identified in two separate high 
through-put screens as positive hits, methyl-3,4-dephostatin and the steroid 
compound NSC8891536 (Figure 37), both share similar structural characteristics as 
the phosphotyrosine substrate. Methyl-3,4-dephostatin is an aromatic amine 
derivative with a hydroxy-substituted benzyl ring, bearing close resemblance to 
the phosphate group linked to the tyrosyl-moiety in the TDP1 substrate. 
NSC88915 and its derivatives contain an aromatic sulfonyl ester group linked to a 
steroid, simulating the phosphate group covalently linked to the tyrosyl moiety on 
one side and the DNA oligonucleotide on the other. Close examination of the 
structure-activity relationship derived from methyl-3,4-dephostatin and NSC88915 
and their respective derivatives is informative. For example, the only difference 
between dephostatin and methyl-3,4-dephostatin is the position of one hydroxyl 
substitution group on the aromatic ring. However, while methyl-3,4-dephostatin 
inhibits TDP1 at sub-micromolar concentrations, dephostatin displays almost no 
activity in the same concentration range. Similarly, NSC88915 and its five 
derivatives only differ by the nature of the substitution at the para position of the 
aromatic ring. While the difference in activity for these six derivatives are within 
10-fold of each other, another derivative lacking the aromatic ring all together lost 
its potency. These results suggest that the aromatic ring linked to a non-
hydrolysable phosphate mimic could potentially be active at inhibiting TDP1. 
Furthermore, both the nature and position of the substitution groups could 
influence the potency of such inhibitors. [24] 
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Figure 37: Chemical structures of (A) Methyl-3,4-dephostatin and (B) general structure of steroid 
derivatives. 
 
 
5.2 TDP2 inhibitors 
As the TDP2 is a newly discovered enzyme, few inhibitors are known that are able of 
blocking its enzymatic activity. Recent studies have shown, however, that deazaflavin 
derivatives selectively inhibit the human TDP2 enzyme in a competitive manner, both 
with recombinant and native TDP2. Moreover, deazaflavin derivatives show potent 
synergy in combination with the Top2 inhibitor etoposide in human prostate cancer 
DU145 cells, and TDP2-dependent synergy in TK6 human lymphoblast and avian DT40 
cells. Therefore, deazaflavin derivatives represent the first suitable platform for the 
development of potent and selective TDP2 inhibitors, although problems were 
encountered because deazaflavin compounds exhibit low cell permeability. Also 
Toxoflavin derivatives inhibit TDP2 at nanomolar concentration. However, toxoflavin 
derivatives suffer from redox activity in biochemical assay. It is likely that TDP2 inhibitors 
will emerge in the near future. 
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Figure 38: Chemical structures of: (A) Deazaflavin and (B) Toxoflavin. 
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Cancer is a major burden of disease worldwide, as the leading cause of death in 
economically developed countries and the second leading cause of death in developing 
countries. It is characterized by an aberrant structure and uncontrolled growth of cells. 
Therapy for cancer treatment differs depending on type and stage of the tumor, but it can 
be identified with common strategies that include surgery, radiotherapy and 
chemotherapy. 
Drugs used as antitumoral agents act by inducing cell cycle arrest or programmed cell 
death (apoptosis); topoisomerases inhibitors can be listed in the first category. 
DNA topoisomerases exist in all living organisms. They are essential enzymes inducing 
DNA modification required during cellular processes such as replication, transcription and 
repair. Human topoisomerases are classified in type I (Top1) and type II (Top2), depending 
on whether they cleave single-stranded or double-stranded DNA, respectively. Top1 binds 
the ribonucleotidic chain, leading to the formation of Top1-DNA cleavage complexes 
(Top1cc). Various conditions can increase the frequency of these complexes, which are 
converted into DNA damage by cellular metabolism or preexisting DNA lesions. 
Tyrosyl-DNA phosphodiesterase I (TDP1) is a recently discovered enzyme that has been 
implicated in the repair of irreversible Top1-DNA covalent complexes, because it catalyzes 
the hydrolytic cleavage of the covalent bond between the Top1 catalytic tyrosine and the 
3’-end of the DNA.  
For this reason, TDP1 has been regarded as a potential co-target of Top1 for anticancer 
therapy, in that it seemingly counteracts the effects of Top1 inhibitors, such as 
camptothecin and its clinically used derivatives. Thus, TDP1 inhibitors have the potential 
to augment the anticancer activity of Top1 inhibitors, by reducing the repair of Top1-DNA 
lesions. 
Within a project aimed to identify new potential TDP1 inhibitors, in collaboration with the 
group of Professor Pommier of NIH (National Institutes of Health, Bethesda), an in vitro 
screening on an in-house library of structurally heterogeneous chemical compounds was 
performed. Three of these molecules (TDP24, RDS2771 and RDS788) showed weak 
inhibitory activity on TDP1, so representing lead compounds to be further improved by a 
lead optimization process (Figure 38).  
48 
 
In collaboration with the research group of Professor Novellino (University of Naples), 
these compounds were used as starting points for a de novo design strategy, by means of 
computational studies. Two of the identified hits, RDS2771 and TDP24, are polyaromatic 
compounds having an alkyl chain with a terminal polar group. From these preliminary 
studies, it is clear that the polar substituents of TDP24 and RDS2771 take direct contact 
with the enzyme residues (Figure 38).  
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Figure 38:  Binding mode of TDP24 (in pink) and RDS2771 (in yellow) predicted in the Tdp1 X-ray structure. 
The protein is represented as green ribbons and sticks.  
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These ligands contain, within their nucleus, an indole ring (TDP24) or a bioisosteric 
pyrrolopyridine (RDS2771), which suggested that properly substituted nitrogen-
cointaining heterocyclic derivatives may potentially act as TDP1 inhibitors.  
Thus, guided by molecular modeling studies on TDP24, two sets of indole derivatives 
featuring an ester (I) or amide function (IIa and IIb) at 3-position, and variously 
substituted with alcoholic and amine chains of different lengths at specific positions, have 
been designed.  
The designed ligands were then subjected to molecular docking studies (University of 
Naples) at the crystal structure of TDP1 (data not shown), that predicted compounds I, IIa 
and IIb as potential TDP1 binders. 
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Target compounds I, IIa and IIb were synthesized following synthetic procedures reported 
in Schemes 1-4. 
The starting key intermediate ethyl 1-benzyl-5-hydroxy-1H-indole-3-carboxylate 5 was 
prepared according to an experimental procedure outlined in Scheme 1.  
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The first step consisted in the formylation of 5-methoxyindole by treatment with 
phosphoryl chloride in dry DMF, and then with a solution of NaOH, to achieve compound 
1, which was subsequently oxidized with potassium permanganate, yielding the 
corresponding carboxylic acid 2, used in the next reaction without any further 
purification. 
The ethyl ester derivative 3 was obtained by Fischer esterification, by refluxing compound 
2 in absolute ethanol for 20 hours, in the presence of a catalytic amount of concentrated 
sulfuric acid.  
The next step consisted in the benzylation of derivative 3, by treatment with benzyl 
bromide in dry DMF, in the presence of NaH, to achieve compound 4, which was purified 
by flash chromatography (eluent mixture – Ethyl acetate:petrouleum ether 40-60 °C = 
3:7).   
Compound 5 was obtained by demethylation of derivative 4, by reaction with boron 
tribromide, added dropwise in nitrogen atmosphere in anhydrous dichloromethane. At 
the end, methanol was added to the reaction mixture to hydrolyze the excess of BBr3, and 
crude 5 was purified by flash chromatography (eluent mixture – ethyl acetate:petrouleum 
ether 40-60 °C = 3:7).  
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The synthetic procedure followed to obtain compounds 6-8 and 10-11 is outlined in 
Scheme 2.  
For the synthesis of derivatives 6-8, Cs2CO3 was added to a solution of compound 5 in 
anhydrous dimethylformamide; contemporaneously, in another flask, Cs2CO3 was added 
to a suspension of 2-chloro-N,N-diethylethylamine hydrochloride (6), or 2-chloro-N,N-
dimethylethylamine hydrochloride (7), or 3-dimethylamino-1-propylchloride 
hydrochloride (8) in the same solvent. The mixtures were stirred for about 30 minutes at 
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room temperature, then were put together and heated at 60°C for about 8h. Then 
dimethylformamide was removed under reduced pressure, and ice was added to the 
flask. The mixture was extracted with DCM and the crude products 6-8 were finally 
purified by flash chromatography (eluent mixture - dichloromethane/methanol = 9:1). 
For the synthesis of derivative 10, compound 5 was treated with 2-bromoethylacetate 
and cesium carbonate in acetone overnight at 60°C, leading to compound 9, which was 
finally hydrolyzed with a solution of NaOH 1M in dioxane, at room temperature for 5 
hours. Then the reaction mixture was concentrated in vacuum, dissolved in ethyl acetate 
and washed with 1) saturated aqueous NaHCO3 solution, 2) water and 3) brine. 
Compounds 9, 10, were purified by flash chromatography (eluent mixture - ethyl 
acetate:petroleum ether 40-60 °C = 3:7 for compound 9; ethyl acetate:petroleum ether 
40-60 °C = 4:6 for compound 10). 
Conversely, compound 11 was directly obtained by treatment of derivative 5 with 
potassium carbonate and 3-bromopropan-1-ol, at 60°C for 48 hours. The suspension was 
filtered off and the filtrate was concentrated under reduced pressure. The crude product 
was then purified by flash chromatography (eluent mixture - ethyl acetate:petroleum 
ether 40-60 °C = 4:6). 
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Scheme 2 
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The synthetic procedure for the obtainment of compounds 14-15 is outlined in Scheme 3. 
Compounds 10, 11 were hydrolyzed by treatment with LiOH·H2O in a MeOH/H2O (3:1) 
solution, in order to obtain the corresponding carboxylic acids 12, 13, which were used in 
the following reaction without any further purification. 
Treatment of 12, 13 with 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate (TBTU), N,N-Diisopropylethylamine (DIPEA) and 3-amino-1-propanol in 
anhydrous dimethylformamide, at room temperature for 24 hours, achieved the 
corresponding amides 14,15, purified by flash chromatography (eluent mixture - 
dichloromethane/methanol = 9:1). 
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Scheme 3 
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Scheme 4 describes the synthesis of compounds 19-22.  
The ethylester derivatives 6-8 were hydrolyzed with LiOH·H2O in a MeOH/H2O (3:1) 
solution, in order to obtain derivatives 16-18, which were then treated with 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), N,N-
Diisopropylethylamine (DIPEA) and ethanolamine or benzylamine in anhydrous 
dimethylformamide, at room temperature for 24 hours, yielding compounds 19-22. 
Derivatives 19-22 were purified by flash chromatography (eluent mixture - 
dichloromethane/methanol = 9:1). 
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Melting points were determined using a Reichert Kofler hot-stage apparatus and are 
uncorrected. Routine nuclear magnetic resonance spectra were recorded in DMSO-d6, 
CDCl3-d6 or MeOD solution on a Bruker spectrometer operating at 400 MHz. Evaporation 
was performed in vacuum (rotary evaporator). Analytical TLC was carried out on Merck 
0.2 mm percolated silica gel aluminium sheets (60 F-254). Silica gel (230-400 mesh ASTM) 
was used for column chromatography. Anhydrous reactions were performed in flame-
dried glassware under N2. All reagents used were obtained from commercial sources. All 
solvents were of an analytical grade.  
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Procedure for the synthesis of 5-methoxy-1H-indole-3-carbaldehyde 1. 
 
Phosphoryl chloride (3.74 mmol) was added to 1.15 mL of dimethylformamide and the 
mixture was stirred for 40 minutes at 0°C. 
Then 5-methoxy-1H-indole (3.40 mmol) in 0.7 mL of dimethylformamide (DMF) was 
added and the solution was stirred at 0°C for 40 minutes and at 35°C for other 40 
minutes. After that ice was added to the reaction mixture along with a solution of NaOH 
(1.496 g, 37.4 mmol in 4 mL H2O) added dropwise. 
The resulting solution was stirred at 100°C for 30 minutes, then at room temperature 
overnight. (TLC analysis: AcOEt: petroleum ether 40-60 °C = 6:4). 
The solid precipitate formed was collected by vacuum filtration, washed with H2O and 
collected again. The crude product did not need any further purification.  
 
5-methoxy-1H-indole-3-carbaldehyde (1). Yield: 84%; mp= 176-178°C; 1H-NMR (DMSO, 
ppm): 12.03 (bs, 1H, exch. D2O); 9.90 (s, 1H); 8.22 (s, 1H); 7.59 (d, 1H, J= 2.4 Hz); 7.41 (d, 
1H, J=8.8 Hz); 6.90, 6.88 (dd, 1H, J= 2.8 Hz, J= 8.8 Hz); 3.79 (s, 3H). 
 
Procedure for the synthesis of 5-methoxy-1H-indole-3-carboxylic acid 2. 
 
To a solution of compound 1 (1.14 mmol) in 5 mL of acetone, a solution of KMnO4 (1.40 
mmol) in 5 mL of H2O was added dropwise and the temperature was maintained 
between 30 and 40°C. After 5 min the purple color of potassium permanganate 
disappeared and the brown precipitate of Mn02 formed.  
The mixture was filtered on a Buchner funnel using Celite filter aid. The filtrate was 
concentrated to dryness and a white precipitate formed after addition of six drops of 6 N 
hydrochloric acid. The precipitate was dissolved in sodium bicarbonate, reprecipitated 
with a few drops of 6 N HCl, and dried. 
The crude product did not need any further purification.  
 
5-methoxy-1H-indole-3-carboxylic acid (2). Yield: 62%; mp= 172-174°C; 1H-NMR (DMSO, 
ppm): 11.69 (bs, 1H, exch. D2O); 7.93 (d, 1H, J= 2.8 Hz); 7.48 (d, 1H, J=2.4 Hz); 7.35 (d, 1H, 
J= 8.8 Hz); 6.83, 6.80 (dd, 1H, J= 2.4 Hz, J= 8.8 Hz); 3.45 (s, 3H). 
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Procedure for the synthesis of ethyl 5-methoxy-1H-indole-3-carboxylate 3. 
 
To a solution of compound 2 (3.00 mmol) in absolute ethanol (52 mL) was added catalytic 
amount of concentrated sulphuric acid (0.52 mL) and allowed to reflux for 20 h. After 
completion of the reaction, ethanol was removed and the residue was extracted with 
ethyl acetate and washed with saturated sodium bicarbonate solution. Organic layer was 
dried over sodium sulphate and evaporated to give corresponding ester. The crude 
product was then purified by flash chromatography (AcOEt: petroleum ether 40-60 °C = 
5:5).   
 
ethyl 5-methoxy-1H-indole-3-carboxylate (3). Yield: 31%; mp= 123-125°C; 1H-NMR (CDCl3, 
ppm): 8.56 (bs, 1H, exch D2O); 7.89 (d, 1H, J= 3.2 Hz); 7.70 (d, 1H, J= 2.8 Hz); 7.32 (d, 1H, 
J= 8.8); 6.94, 6.92 (dd, 1H, J=8.8 Hz, J=2.4 Hz); 4.41 (q, 2H, J=7.2 Hz); 3.91 (s, 3H); 1.45 (t, 
3H, J=7.0 Hz). 
 
Procedure for the synthesis of ethyl 1-benzyl-5-methoxy-1H-indole-3-carboxylate 4. 
 
Sodium hydride (1.00 mmol, 60% dispersion in mineral oil) was added portionwise, under 
nitrogen atmosphere, to an ice-cold solution of compound 3 (0.200 g, 0.91 mmol) in 
dimethylformamide (5ml) and the mixture was stirred for about 30 minutes at 0°C.  
Once hydrogen evolution ceased, benzyl bromide (1.00 mmol) was added dropwise and 
the reaction was maintained under stirring for 5 hours at room temperature.  
After completion of the reaction, DMF was evaporated under reduced pressure, then ice 
was added to the flask and the solid precipitate formed was collected by vacuum 
filtration. The crude product was then purified by flash chromatography (AcOEt: 
petroleum ether 40-60 °C = 3:7).   
 
1-benzyl-5-methoxy-1H-indole-3-carboxylate (4). Yield: 83%; mp=89-91°C; 1H-NMR 
(DMSO-d6, ppm): 8.24 (s, 1H); 7.50 (d, 1H, J=2.4 Hz); 7.44 (d, 1H, J=9.2 Hz); 7.35-7.25 (m, 
5H); 6.85, 6.83 (dd, 1H, J=2.4 Hz, J=8.8 Hz), 5.47 (s, 2H); 4.28 (q,2H, J=7.0 Hz); 3.78 (s, 3H); 
1.34 (t, 3H, J=7.0 Hz). 
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Procedure for the synthesis of ethyl 1-benzyl-5-hydroxy-1H-indole-3-carboxylate 5. 
 
To a solution of compound 4 (0.65 mmol) in anhydrous dichloromethane (DCM) (5 ml), 
cooled at -10°C, was added boron tribromide (1.10 mL, 6.5 mmol) in 1 ml of the same 
solvent. The mixture was stirred for 4 hours at room temperature. The dichloromethane 
was evaporated under reduced pressure and the residue was then washed twice with 
ethanol to hydrolyze the excess of BBr3; the product obtained was finally purified by flash 
chromatography (AcOEt: Petroleum Ether 40-60 °C = 3:7). 
 
ethyl 1-benzyl-5-hydroxy-1H-indole-3-carboxylate (5). Yield: 54%; mp= 175-177 °C; 1H-
NMR (DMSO-d6, ppm): 9.08 (bs, 1H, exch D2O); 8.16 (s, 1H); 7.39 (d, 1H, J=2.0 Hz); 7.35-
7.25 (m, 6H); 6.70, 6.67 (dd, 1H, J=2.4 Hz, J=8.8 Hz); 5.42 (s, 2H); 4.26 (q, 2H, J=7.2 Hz); 
1.33 (t, 3H, J= 7.2 Hz). 
 
Procedure for the synthesis of ethyl 5-(2-(dialkylamino)alkyoxy-1-benzyl-1H-indole-3-
carboxylate 6-8. 
 
In a flask, Cs2CO3 (0.35 mmol) was added to a solution of compound 5 (0.27 mmol) in 
anhydrous dimethylformamide (5 ml); in another flask, Cs2CO3 (0.49 mmol) was added to 
a suspension of the appropriate amine (0.43 mmol) in the same solvent. The reaction was 
conducted under nitrogen. The mixtures were stirred for about 30 minutes at room 
temperature, then the two flasks were put together and the resulting mixture was heated 
at 60 °C for about 8h (TLC analysis: dichloromethane/methanol = 9:1). The 
dimethylformamide was removed under reduced pressure, and ice was added to the 
flask. The mixture was extracted with DCM and, after drying with MgSO4, DCM was 
evaporated to dryness to yield the crude products, which were purified by flash 
chromatography (DCM: MeOH = 9:1).    
 
ethyl 5-(2-(diethylamino)ethoxy)-1-benzyl-1H-indole-3-carboxylate (6). Yield: 42%; mp= 
48-50°C; 1H-NMR (CDCl3, ppm): 7.81 (s, 1H); 7.71 (d, 1H, J= 2.4 Hz); 7.35-7.29 (m,3H); 
7.18-7.13 (m, 3H); 6.91, 6.88 (dd, 1H, J= 2.4 Hz, J=8.8 Hz); 5.29 (s, 2H); 4.39 (q, 2H, J=7.2 
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Hz); 4.20 (t, 2H, J=6.2 Hz); 2.99 (t, 2H, J=6.2 Hz); 2.74 (q, 4H, J=7.2 Hz); 1.42 (t, 3H, J=7.0 
Hz); 1.14 (t, 6H, J=7.2 Hz). 
 
ethyl 5-(2-(dimethylamino)ethoxy)-1-benzyl-1H-indole-3-carboxylate (7).  Yield: 30%;    
mp= 69-71 °C; 1H-NMR (CDCl3, ppm): 7.82 (s, 1H); 7.71 (d, 1H, J=2.4 Hz); 7.36-7.31 (m, 
3H); 7.19-7.14 (m, 3H); 6.94, 6.92 (dd, 1H, J=2.6 Hz, J=9.0 Hz); 5.31 (s, 1H); 4.39 (q, 2H, J= 
7.2 Hz); 4.21 (t, 2H, J= 5.6 Hz); 2.85 (t, 2H, J= 5.4 Hz); 2.42 (s, 6H); 1.42 (t, 3H, J= 7.0 Hz). 
 
ethyl 5-(3-(dimethylamino)propoxy)-1-benzyl-1H-indole-3-carboxylate (8). Yield:88%; mp=  
58-60 °C; 1H-NMR (CDCl3, ppm): 7.81 (s, 1H); 7.69 (d, 1H, J=2.4 Hz); 7.36-7.31 (m, 3H); 
7.19-7.14 (m, 3H); 6.89, 6.87 (dd, 1H, J=2.6 Hz, J=9.0 Hz); 5.31 (s, 2H); 4.39 (q, 2H, J=7.2 
Hz); 4.12 (t, 2H, J= 6.2 Hz); 2.69 (t, 2H, J=7.6 Hz); 2.42 (s, 6H); 2.14-2.07 (m, 2H); 1.43 (t, 
3H, J= 7.0 Hz). 
 
Procedure for the synthesis of ethyl 5-(2-ethylacetate)-1-benzyl-1H-indole-3-
carboxylate 9. 
 
To a solution of compound 5 (0.34mmol) in acetone (16 ml) was added cesium carbonate 
(1.02 mmol) and 2-bromoethyl acetate (0.51 mmol). The mixture was stirred at 60 °C 
overnight (TLC analysis: ethyl acetate/ petroleum ether 40-60 °C =3:7), concentrated in 
vacuum and suspended in ethyl acetate. The suspension was washed with 1) H2O; 2) 
saturated aqueous NaHCO3 solution and 3) brine. The organic phase was dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was then 
purified by flash chromatography (ethyl acetate/ petroleum ether 40-60 °C =3:7).   
 
ethyl 5-(2-ethylacetate)-1-benzyl-1H-indole-3-carboxylate (9). Yield: 69% mp= 115-117 °C; 
1H-NMR (CDCl3, ppm): 7.83 (s, 1H); 7.72 (d, 1H, J=2.4 Hz); 7.35-7.28 (m, 3H); 7.20 (d, 1H, 
J=8.8 Hz); 7.17-7.14 (m, 2H); 6.94, 6.91 (dd, 1H, J=2.4 Hz, J=8.8 Hz); 5.33 (s, 2H); 4.49-4.46 
(m, 2H); 4.40 (q, 2H, J=7.1 Hz); 4.30-4.27 (m, 2H); 2.13 (s, 3H); 1.43 (t, 3H, J= 7.2 Hz). 
 
62 
 
Procedure for the synthesis of ethyl 5-(2-hydroxyethoxy)-1-benzyl-1H-indole-3-
carboxylate 10. 
 
A solution of compound 9 (0.23 mmol) was dissolved in 1,4-dioxane (6.5 ml) and cooled at 
0 °C. Then a solution of NaOH 1M (1.0 ml) was added and the mixture was stirred at room 
temperature for 5 hours. The reaction mixture was concentrated in vacuum, dissolved in 
ethyl acetate and washed with 1) saturated aqueous NaHCO3 solution, 2) water and 3) 
brine. The organic phase was dried over MgSO4  and concentrated under reduced 
pressure. The crude product was then purified by flash chromatography (ethyl acetate/ 
petroleum ether 40-60 °C =4:6).   
ethyl 5-(2-hydroxyethoxy)-1-benzyl-1H-indole-3-carboxylate (10). Yield: 64%; mp= 118-120 
°C; 1H-NMR (CDCl3, ppm): 7.83 (s, 1H); 7.73 (d, 1H, J= 2.4 Hz); 7.36-7.31 (m, 3H); 7.21-7.15 
(m, 3H); 6.93, 6.91 (dd, 1H, J= 2.6 Hz, J= 9.0 Hz); 5.33 (s, 2H); 4.40 (q, 2H, J= 7.2Hz); 4.20 (t, 
2H, J= 4.4 Hz); 4.12 (t, 2H, J= 4.4 Hz); 1.43 (t, 5H, J= 7.2 Hz). 
 
Procedure for the synthesis of ethyl 5-(3-hydroxypropoxy)-1-benzyl-1H-indole-3-
carboxylate 11. 
 
Potassium carbonate (1.00 mmol) and 3-bromo-1-propanol (0.020 ml, 0.30 mmol) were 
added to a solution of compound 5 (0.20 mmol) in acetone (6 ml). The mixture was 
stirred at 60°C for about 48 hours (TLC analysis: ethyl acetate/ petroleum ether 40-60 °C 
=4:6). The suspension was filtered off, and the filtrate was concentrated under reduced 
pressure. The crude product was then purified by flash chromatography (AcOEt: 
Petroleum Ether 40-60 °C = 4:6). 
 
ethyl 5-(3-hydroxypropoxy)-1-benzyl-1H-indole-3-carboxylate (11). Yield:36%; mp= 120-
122 °C; 1H-NMR (CDCl3, ppm): 7.82 (s, 1H); 7.73 (d, 1H, J=2.4 Hz); 7.37-7.30 (m, 3H); 7.20-
7.14 (m, 3H); 6.90, 6.88 (dd, 1H, J=2.6, J= 9.0 Hz); 5.32 (s, 2H); 4.39 (q, 2H, J=7.2 Hz); 4.24 
(t, 2H, J=6.0 Hz); 3.91 (t, 2H, J= 6.0 Hz); 2.10 (q, 2H, J= 6.0 Hz); 1.43 (t, 3H, J=7.2 Hz). 
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Procedure for the synthesis of 1-benzyl-5-(hydroxyalkoxy)-1H-indole-3-carboxylic acid 
12-13. 
 
LiOH·H2O (0.42 mmol) was added to an ice-cooled solution of the appropriate derivative 
10 or 11 (0.42 mmol) in 8 mL of MeOH/H2O mixture (3:1). The resulting mixture was 
refluxed overnight (TLC analysis: ethyl acetate/ petroleum ether 40-60 °C =5:5). The 
suspension was filtered off, and the filtrate was acidified until pH=1.  
The mixture was extracted with DCM and, after drying with MgSO4, the solvent was 
evaporated to dryness to yield the crude products 12 and 13, which not need any further 
purification. 
 
5-(2-hydroxyethoxy)-1-benzyl-1H-indole-3-carboxylic acid (12). Yield:92%; mp= 160-162 
°C; 
1H-NMR (DMSO-d6, ppm): 11.97 (bs, 1H, exch. D2O); 8.15 (s, 1H); 7.50 (d, 1H, J= 2.4 Hz); 
7.41 (d, 1H, J= 8.8 Hz); 7.35-7.31 (m, 2H); 7.29-7.25 (m, 3H); 6.85, 6.83 (dd, 1H, J=2.6 Hz, 
J=8.0 Hz); 5.45 (s, 2H); 4.83 (bs, 1H, exch. D2O); 3.98 (t, 2H, J=5.0 Hz); 3.73 (q, 2H, J=4.6 
Hz). 
 
5-(3-hydroxypropoxy)-1-benzyl-1H-indole-3-carboxylic acid (13). Yield:51%;                  
mp=168-170 °C; 1H-NMR (DMSO-d6, ppm): 11.97 (bs, 1H, exch. D2O); 8.15 (s, 1H); 7.50 (d, 
1H, J= 2.4 Hz); 7.41 (d, 1H, J= 8.8 Hz); 7.35-7.29 (m, 2H); 7.28-7.25 (m, 3H); 6.83, 6.81 (dd, 
1H, J= 2.6 Hz, J= 9.0 Hz); 5.45 (s, 2H); 4.54 (t, 1H, J= 5.2Hz, exch D2O); 4.03 (t, 2H, J= 6.6 
Hz); 3.57 (q, 2H, J= 6.0 Hz); 1.92-1.85 (m, 2H). 
 
Procedure for the synthesis of 5-(hydroxyalkoxy)-1-benzyl-N-(2-hydroxyethyl)-1H-
indole-3-carboxamide 14-15. 
 
An ice-cooled solution of the appropriate derivative 12 or 13 (0.21 mmol) in anhydrous 
dimethylformamide, was treated with 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate  (TBTU) and N,N-Diisopropylethylamine (DIPEA). 
The resulting mixture was stirred for 30 minutes, then 3-amino-1-propanol ( 0.21 mmol) 
64 
 
was added and the mixture was stirred at room temperature for about 24 hours  (TLC 
analysis: dichloromethane/methanol = 9:1). The dimethylformamide was removed under 
reduced pressure, and ice was added to the flask. The solid precipitate formed was 
collected by vacuum filtration. The crude products were then purified by flash 
chromatography (dichloromethane/methanol = 9:1). 
 
5-(2-hydroxyethoxy)-1-benzyl-N-(3-hydroxypropyl)-1H-indole-3-carboxamide (14). 
Yield:83%;  mp=134-136 °C; 1H-NMR (MeOD, ppm): 7.86 (s, 1H); 7.69 (d, 1H, J=2.4 Hz); 
7.33-7.25 (m, 4H); 7.20-7.18 (m, 2H); 6.91, 6.89 (dd, 1H, J=2.4 Hz, J=9.2 Hz); 5.37 (s, 2H); 
4.11 (t, 2H, J=4.8 Hz); 3.90 (t, 2H, J=4.8 Hz); 3.69 (t, 2H, J=6.2 Hz); 3.50 (t, 2H, J=6.8 Hz); 
1.86 (q, 2H, J=6.4 Hz). 
 
5-(3-hydroxypropoxy)-1-benzyl-N-(3-hydroxypropyl)-1H-indole-3-carboxamide (15). Yield: 
34%; mp= 125-127 °C; 1H-NMR (CDCl3, ppm): 7.76 (s, 1H); 7.58 (d, 1H, J=2.4 Hz); 7.33-7.29 
(m, 3H); 7.17 (d, 1H, J=8.8 Hz); 7.13-7.11 (m, 2H); 6.88, 6.85 (dd, 1H, J=2.4 Hz, J=9.2 Hz); 
4.21 (t, 2H, J=6.2 Hz); 3.88 (t, 2H, J=5.8 Hz); 3.75 (t, 2H, J=5.6 Hz); 3.65 (t, 2H, J=5.8 Hz); 
2.09-2.03 (m, 2H); 1.83-1.79 (m, 2H). 
 
Procedure for the synthesis of 5-((alkylamino)alkoxy)-1-benzyl-1H-indole-3-carboxylic 
acid 16-18. 
 
LiOH·H2O (0.49 mmol) was added to an ice-cooled solution of the appropriate derivative 6 
or 7 or 8 (0.81 mmol), in 8 mL of MeOH/H2O mixture (3:1). The resulting mixture was 
refluxed overnight (TLC analysis: dichloromethane/methanol = 9:1). The suspension was 
filtered off, and the filtrate was acidified until pH=1.  
The mixture was extracted with DCM and, after drying with MgSO4, the solvent was 
evaporated to dryness to yield the crude products 16-18, which not need any further 
purification. 
 
5-(2-(diethylamino)ethoxy)-1-benzyl-1H-indole-3-carboxylic acid (16). Yield:90%; mp= 94-
96 °C; 1H-NMR (DMSO-d6, ppm): 8.21 (s, 1H), 7.57 (d, 1H, J= 2.4 Hz); 7.47 (d, 1H, J= 9.2 
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Hz); 7.35-7.29 (m, 2H); 7.27-7.25 (m, 3H); 6.92, 6.89 (dd, 1H, J=2.4 Hz, J=9.2 Hz); 5.48 (s, 
2H); 4.35 (t, 2H, J=4.6 Hz); 3.52-3.50 (m, 2H); 3.23-3.21 (m, 4H); 1.25 (t, 6H, J=7.2 Hz). 
 
5-(2-(dimethylamino)ethoxy)-1-benzyl-1H-indole-3-carboxylic acid (17). Yield:81%; mp= 
130-132°C; 1H-NMR (MeOD, ppm): 8.06 (s, 1H); 7.73 (d, 1H, J= 2.0 Hz); 7.37-7.27 (m, 4H); 
7.23-7.21 (m, 2H); 6.96, 6.98 (dd, 1H, J= 8.8 Hz, J= 2.0 Hz); 5.45 (s, 2H); 4.41-4.40 (m, 2H); 
3.63-3.61 (m, 2H); 3.01 (s, 6H). 
 
5-(3-(dimethylamino)propoxy)-1-benzyl-1H-indole-3-carboxylic acid (18). Yield:97%; oil; 
1H-NMR (MeOD, ppm): 8.00 (s, 1H); 7.64 (d, 1H, J= 2.4 Hz); 7.32-7.29 (m, 4H); 7.27-7.19 
(m, 2H); 6.88,6.86 (dd, 1H, J=2.4 Hz, J=9.2 Hz); 5.41 (s, 2H); 4.16 (t, 2H, J=5.8 Hz); 3.38 (t, 
2H, J= 7.6 Hz); 2.94 (s, 6H); 2.25-2.21 (m, 2H). 
 
Procedure for the synthesis of 5-(2-(diethylamino)ethoxy)-N,1-dibenzyl-1H-indole-3-
carboxamide 19. 
 
An ice-cooled solution of the derivative 16 (0.34 mmol) in anhydrous dimethylformamide, 
was treated with 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate  
(TBTU) and N,N-Diisopropylethylamine (DIPEA), the mixture was stirred for 30 minutes, 
then benzylamine (0.34 mmol) was added and the mixture was stirred at room 
temperature overnight (TLC analysis: dichloromethane/methanol = 9:1). The 
dimethylformamide was removed under reduced pressure and then ice was added to the 
flask. The mixture was extracted with ethyl acetate and the organic phase was dried over 
MgSO4 filtered and concentrated under reduced pressure. The crude product was then 
purified by flash chromatography (dichloromethane/methanol = 9:1). 
 
5-(2-(diethylamino)ethoxy)-N,1-dibenzyl-1H-indole-3-carboxamide (19). Yield:16%; mp= 
57-59 °C; 1H-NMR (MeOD, ppm): 7.99 (s, 1H); 7.79 (d, 1H, J=2.4 Hz); 7.41-7.30 (m, 5H); 
7.29-7.22 (m, 4H); 7.22-7.20 (m, 2H); 6.95, 6.93 (dd, 1H, J=2.6 Hz, J=9.0 Hz); 5.42 (s, 2H); 
4.60 (s, 2H); 4.35 (t, 2H, J=5.0 Hz); 3.52 (t, 2H, J=5.0 Hz); 3.26 (q, 4H, J=7.4 Hz); 1.34 (t, 6H, 
J=7.2 Hz). 
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Procedure for the synthesis 5-(2-(dialkylamino)alkoxy)-1-benzyl-N-(2-hydroxyethyl)-1H-
indole-3-carboxamide 20-22. 
 
An ice-cooled solution of the appropriate derivative 16 or 17 or 18 (0.25 mmol) in 
anhydrous dimethylformamide, was treated with 2-(1H-Benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium tetrafluoroborate  (TBTU) and N,N-Diisopropylethylamine (DIPEA) 
and the mixture was stirred for 30 minutes. Then ethanolamine (0.25 mmol) was added 
and the mixture was stirred at room temperature overnight (TLC analysis: 
dichloromethane/methanol = 9:1). The dimethylformamide was removed under reduced 
pressure and ice was added to the flask. The mixture was extracted with dichloromethane 
and the organic phase was dried over MgSO4 and concentrated under reduced pressure. 
The crude product was then purified by flash chromatography 
(dichloromethane/methanol = 9:1).  
 
5-(2-(diethylamino)ethoxy)-1-benzyl-N-(2-hydroxyethyl)-1H-indole-3-carboxamide (20). 
Yield: 20% ; oil; 1H-NMR (MeOD, ppm): 7.88 (s, 1H); 7.42 (d, 1H, J=2.8 Hz); 7.35-7.26 (m, 
4H); 7.22-7.20 (m, 2H); 6.96, 6.93 (dd, 1H, J=2.4 Hz, J=9.2 Hz); 5.43 (s, 2H); 4.37 (t, 2H, 
J=5.0 Hz); 3.74 (q, 4H, J=6.8 Hz); 3.62 (t,2H, J=4.8 Hz); 3.37 (m, 2H); 3.25 (m, 2H); 1.38 (t, 
6H, J=7.2 Hz). 
 
5-(2-(dimethylamino)ethoxy)-1-benzyl-N-(2-hydroxyethyl)-1H-indole-3-carboxamide (21). 
Yield: 27%; oil; 1H-NMR (MeOD, ppm): 7.93 (s, 1H); 7.73 (d, 1H, J=2.4 Hz); 7.34-7.26 (m, 
4H); 7.26-7.19 (m, 2H); 6.92, 6.90 (dd, 1H, J=2.6 Hz, J=9.0 Hz); 4.25 (t, 2H, J=5.2 Hz); 3.74 
(t, 2H, J=5.8 Hz); 3.53 (t, 2H, J=5.8 Hz); 3.09 (t, 2H, J= 5.2 Hz); 2.59 (s, 6H). 
 
5-(3-(dimethylamino)propoxy)-1-benzyl-N-(2-hydroxyethyl)-1H-indole-3-carboxamide (22). 
Yield: 23%; oil; 1H-NMR (MeOD, ppm): 7.92 (s, 1H); 7.70 (d, 1H, J=2.4 Hz); 7.32-7.26 (m, 
4H); 7.19-7.17 (m, 2H); 6.87, 6.85 (dd, 1H, J=2.4 Hz, J=8.8 Hz); 5.38 (s, 2H); 4.63 (t, 2H, 
J=5.4 Hz); 4.16 (t, 2H, J=5.6 Hz); 3.72 (t, 2H, J=5.8 Hz); 3.64 (t, 2H, J=5.4 Hz); 3.51 (t, 2H, 
J=5.8 Hz); 2.89 (s,6H). 
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